ArticleInternational journal of surgery (London, England)2026
Cholangiocarcinoma in Denmark: time trends in mortality following resection.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time trends in mortality risk after resection in a nationwide Danish cohort.
methodsWe identified all Danish citizens diagnosed with cholangiocarcinoma in 2004-2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two. We computed the proportions of patients who received downstaging or adjuvant chemotherapy, and we estimated age- and sex-adjusted mortality risks.
resultsBetween 2004 and 2022, 611 patients with cholangiocarcinoma underwent resection (13% of 4572 patients with cholangiocarcinoma). The proportion who underwent resection increased from 9% in 2004-2012 to 16% in 2018-2022, the median age of resected patients rose from 65 to 69 years, and the proportion with comorbidities increased from 17% to 28%. In patients who underwent liver resection, the proportion who had received downstaging chemotherapy increased from <7% in 2004-2012 to 12% (8-20), and the proportion who received adjuvant chemotherapy increased from 27% (18-39) in 2004-2012 to 49% (40-58) in 2018-2022. Despite the increasing use of chemotherapy before and after liver resection, age- and sex-adjusted mortality remained essentially the same, with 1-year mortality ranging from 14% to 20% ( P -value = 0.37). In patients who underwent biliary tract resection, only 3% received downstaging chemotherapy, but the proportion who received adjuvant therapy increased from 17% (10-29) in 2004-2012 to 59% (48-68) in 2018-2022. Even so, these patients' age- and sex-adjusted mortality remained stable (1-year mortality ranging from 19% to 24%, P -value = 0.34).
conclusionThe proportion of patients with cholangiocarcinoma who underwent liver or biliary tract resection increased, and more patients received downstaging chemotherapy and adjuvant chemotherapy. Nonetheless, age- and sex-adjusted mortality risks remained constant. The explanations for this pattern are unclear but likely involve changing patient characteristics other than age and sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.